Sort
10,766 grants matching “checkpoint inhibitor”
Role of PI3Kinase in Tumor Progression and Metastasis
$308,036Judith A. Varner · University Of California, San Diego · R01 · FY2018 · CA
In Vivo Regulation and Inhibition of Ribonucleotide Reductase
$308,034Mingxia Huang · University Of Colorado Denver · R01 · FY2011 · CA
In Vivo Regulation and Inhibition of Ribonucleotide Reductase
$308,034Mingxia Huang · University Of Colorado Denver · R01 · FY2012 · CA
XLF in double-strand break repair and chemo/radiosensitization
$307,872Lawrence F Povirk · Virginia Commonwealth University · R01 · FY2016 · CA
Roles of Lig3 and XRCC1 Genes in Genome Stability
$307,800Alan E Tomkinson · University Of New Mexico Health Scis Ctr · R01 · FY2017 · ES
Roles of Lig3 and XRCC1 Genes in Genome Stability
$307,800Alan E Tomkinson · University Of New Mexico Health Scis Ctr · R01 · FY2020 · ES
Roles of Lig3 and XRCC1 Genes in Genome Stability
$307,800Alan E Tomkinson · University Of New Mexico Health Scis Ctr · R01 · FY2019 · ES
XLF in double-strand break repair and chemo/radiosensitization
$307,700Matthew C Hartman · Virginia Commonwealth University · R01 · FY2017 · CA
Project 2: Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance
$307,307Arlene H Sharpe · Harvard Medical School · U54 · FY2021 · CA
Function and Regulation of Pin2/TRF1 and PinX1
$307,230Beth Israel Deaconess Medical Center · R01 · FY2002 · GM
Controllable In Vivo Genome Editing for Immune-Checkpoint Blockade in Solid Tumors
$307,164Sheng Tong · University Of Kentucky · R01 · FY2019 · EB
Mechanisms of immunomodulation with epigenetic therapy
$306,956Nilofer S. Azad · Johns Hopkins University · P01 · FY2023 · CA
Prostate cancer chemoprevention by penta-galloyl-glucose
$306,945Junxuan Lu · University Of Minnesota · R01 · FY2011 · CA
Translation of Evolved Oncolytic Virotherapy Product for Colorectal Cancer Treatment
$306,871Adam J Schieferecke · Vivere Oncotherapies, Inc. · R41 · FY2025 · CA
Mechanisms of immunomodulation with epigenetic therapy
$306,762Nilofer S. Azad · Johns Hopkins University · P01 · FY2022 · CA
Inhibitors of ENPP1 for the treatment of hepatocellular carcinoma
$306,739Deepa Sengupta · Riboscience, Llc · R41 · FY2025 · CA
Mrad9 Radioresistance Gene
$306,682Columbia University Health Sciences · R01 · FY2002 · CA
Targeting EGFL6 in Ovarian Cancer
$306,593Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
$306,593Robert C Bast · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Cyclin-Dependent Kinase Inhibition During S Phase
$306,173Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2012 · CA
Cyclin-Dependent Kinase Inhibition During S Phase
$306,173Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2011 · CA
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity
$306,041Vlad C Sandulache · University Of Tx Md Anderson Can Ctr · U54 · FY2022 · CA
Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
$305,980Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · P50 · FY2024 · CA
INTEGRATION OF ONCOGENIC SIGNALS BY THE NUCLEOLAR ARF-NPM NETWORK
$305,938Jason Weber · Washington University · R01 · FY2012 · CA
INTEGRATION OF ONCOGENIC SIGNALS BY THE NUCLEOLAR ARF-NPM NETWORK
$305,938Jason Weber · Washington University · R01 · FY2011 · CA